Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
复制标题
通过斑点印迹测量血清 HER2 水平：一种有效且廉价的监测乳腺癌进展的检测方法。
DOI：
10.1371/journal.pone.0018764
复制
发表时间：
2011-04-13
期刊：
影响因子：
3.7
通讯作者：
Feng YM
中科院分区：
文献类型：
--
作者：
Tan LD;Xu YY;Yu Y;Li XQ;Chen Y;Feng YM
人表皮生长因子受体2（HER2）是乳腺癌患者最重要的预后和预测因素之一。最近，通过酶联免疫吸附测定（ELISA）检测患者血清HER2 ECD水平已被证明可以预测肿瘤HER2状态并揭示其与肿瘤进展、复发和不良预后的关系。在本研究中，我们建立了一种新方法——斑点印迹法，来测量乳腺癌患者的血清HER2水平，并进一步评估监测乳腺癌进展的临床价值。我们发现，斑点印迹法测得的血清HER2水平与乳腺癌患者的组织HER2状态显着相关（P = 0.001），与ELISA测得的HER2水平也显着相关（P = 1.06×10−11）。与ELISA法相比，斑点印迹法的特异性和敏感性分别为95.3%和65.0%。 Ⅲ级或ER阴性患者血清HER2水平分别高于I～II级患者（P = 0.004）和ER阳性患者（P = 0.033）。因此，检测血清 HER2 水平的新型斑点印迹方法是一种有效且廉价的检测方法，具有在临床情况下监测乳腺癌进展的潜在应用。
Human epidermal growth factor receptor 2 (HER2) is one of the most important prognostic and predictive factors for breast cancer patients. Recently, serum HER2 ECD level of patients detected by enzyme-linked immunoabsorbent assay (ELISA) has been shown to predict tumor HER2 status and reveal its association with tumor progression, recurrence and poor prognosis. In this study, we established a new method, dot blot assay, to measure the serum HER2 level in breast cancer patients and further to evaluate the clinical value for monitoring breast cancer progression. We found that the serum HER2 level measured by dot blot assay was significantly correlated with tissue HER2 status in breast cancer patients (P = 0.001), and also significantly correlated with HER2 level measured by ELISA (P = 1.06×10−11). Compared with ELISA method, the specificity and sensitivity of dot blot assay were 95.3% and 65.0%, respectively. The serum HER2 levels of patients with grade III or ER-negative were higher than those with grade I–II (P = 0.004) and ER-positive (P = 0.033), respectively. Therefore, the novel dot blot method to detect serum HER2 level is a valid and inexpensive assay with potential application in monitoring breast cancer progression in clinical situations.
登录
查看更多内容
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者：
Thun, Michael J.
影响因子：
45.3
作者：
Cobleigh, MA;Vogel, CL;Slamon, DJ
通讯作者：
Slamon, DJ
影响因子：
45.3
作者：
Burstein, HJ;Harris, LN;Winer, EP
通讯作者：
Winer, EP
影响因子：
50.5
作者：
Fornier, MN;Seidman, AD;Hudis, C
通讯作者：
Hudis, C
影响因子：
56.9
作者：
SLAMON, DJ;CLARK, GM;MCGUIRE, WL
通讯作者：
MCGUIRE, WL